Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Circulation ; 148(11): 862-871, 2023 09 12.
Article in English | MEDLINE | ID: mdl-37555345

ABSTRACT

BACKGROUND: Ventricular arrhythmia is an important cause of mortality in patients with ischemic left ventricular dysfunction. Revascularization with coronary artery bypass graft or percutaneous coronary intervention is often recommended for these patients before implantation of a cardiac defibrillator because it is assumed that this may reduce the incidence of fatal and potentially fatal ventricular arrhythmias, although this premise has not been evaluated in a randomized trial to date. METHODS: Patients with severe left ventricular dysfunction, extensive coronary disease, and viable myocardium were randomly assigned to receive either percutaneous coronary intervention (PCI) plus optimal medical and device therapy (OMT) or OMT alone. The composite primary outcome was all-cause death or aborted sudden death (defined as an appropriate implantable cardioverter defibrillator therapy or a resuscitated cardiac arrest) at a minimum of 24 months, analyzed as time to first event on an intention-to-treat basis. Secondary outcomes included cardiovascular death or aborted sudden death, appropriate implantable cardioverter defibrillator (ICD) therapy or sustained ventricular arrhythmia, and number of appropriate ICD therapies. RESULTS: Between August 28, 2013, and March 19, 2020, 700 patients were enrolled across 40 centers in the United Kingdom. A total of 347 patients were assigned to the PCI+OMT group and 353 to the OMT alone group. The mean age of participants was 69 years; 88% were male; 56% had hypertension; 41% had diabetes; and 53% had a clinical history of myocardial infarction. The median left ventricular ejection fraction was 28%; 53.1% had an implantable defibrillator inserted before randomization or during follow-up. All-cause death or aborted sudden death occurred in 144 patients (41.6%) in the PCI group and 142 patients (40.2%) in the OMT group (hazard ratio, 1.03 [95% CI, 0.82-1.30]; P=0.80). There was no between-group difference in the occurrence of any of the secondary outcomes. CONCLUSIONS: PCI was not associated with a reduction in all-cause mortality or aborted sudden death. In patients with ischemic cardiomyopathy, PCI is not beneficial solely for the purpose of reducing potentially fatal ventricular arrhythmias. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01920048.


Subject(s)
Defibrillators, Implantable , Ventricular Dysfunction, Left , Humans , Male , Aged , Female , Stroke Volume , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/etiology , Death, Sudden, Cardiac/prevention & control , Ventricular Function, Left , Arrhythmias, Cardiac/etiology , Ventricular Dysfunction, Left/etiology , Defibrillators, Implantable/adverse effects , Treatment Outcome
2.
Eur Radiol ; 31(6): 3923-3930, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33215248

ABSTRACT

OBJECTIVES: Aortic stenosis (AS) is characterised by a long and variable asymptomatic course. Our objective was to use cardiovascular magnetic resonance imaging (MRI) to assess progression of adverse remodeling in asymptomatic AS. METHODS: Participants from the PRIMID-AS study, a prospective, multi-centre observational study of asymptomatic patients with moderate to severe AS, who remained asymptomatic at 12 months, were invited to undergo a repeat cardiac MRI. RESULTS: Forty-three participants with moderate-severe AS (mean age 64.4 ± 14.8 years, 83.4% male, aortic valve area index 0.54 ± 0.15 cm2/m2) were included. There was small but significant increase in indexed left ventricular (LV) (90.7 ± 22.0 to 94.5 ± 23.1 ml/m2, p = 0.007) and left atrial volumes (52.9 ± 11.3 to 58.6 ± 13.6 ml/m2, p < 0.001), with a decrease in systolic (LV ejection fraction 57.9 ± 4.6 to 55.6 ± 4.1%, p = 0.001) and diastolic (longitudinal diastolic strain rate 1.06 ± 0.2 to 0.99 ± 0.2 1/s, p = 0.026) function, but no overall change in LV mass or mass/volume. Late gadolinium enhancement increased (2.02 to 4.26 g, p < 0.001) but markers of diffuse interstitial fibrosis did not change significantly (extracellular volume index 12.9 [11.4, 17.0] ml/m2 to 13.3 [11.1, 15.1] ml/m2, p = 0.689). There was also a significant increase in the levels of NT-proBNP (43.6 [13.45, 137.08] pg/ml to 53.4 [19.14, 202.20] pg/ml, p = 0.001). CONCLUSIONS: There is progression in cardiac remodeling with increasing scar burden even in asymptomatic AS. Given the lack of reversibility of LGE post-AVR and its association with long-term mortality post-AVR, this suggests the potential need for earlier intervention, before the accumulation of LGE, to improve the long-term outcomes in AS. KEY POINTS: • Current guidelines recommend waiting until symptom onset before valve replacement in severe AS. • MRI showed clear progression in cardiac remodeling over 12 months in asymptomatic patients with AS, with near doubling in LGE. • This highlights the need for potentially earlier intervention or better risk stratification in AS.


Subject(s)
Aortic Valve Stenosis , Contrast Media , Aged , Aortic Valve Stenosis/diagnostic imaging , Echocardiography , Female , Gadolinium , Humans , Male , Middle Aged , Prospective Studies , Ventricular Function, Left , Ventricular Remodeling
3.
Eur Radiol ; 29(5): 2340-2349, 2019 May.
Article in English | MEDLINE | ID: mdl-30488106

ABSTRACT

OBJECTIVES: To compare aortic size and stiffness parameters on MRI between bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV) patients with aortic stenosis (AS). METHODS: MRI was performed in 174 patients with asymptomatic moderate-severe AS (mean AVAI 0.57 ± 0.14 cm2/m2) and 23 controls on 3T scanners. Valve morphology was available/analysable in 169 patients: 63 BAV (41 type-I, 22 type-II) and 106 TAV. Aortic cross-sectional areas were measured at the level of the pulmonary artery bifurcation. The ascending and descending aorta (AA, DA) distensibility, and pulse wave velocity (PWV) around the aortic arch were calculated. RESULTS: The AA and DA areas were lower in the controls, with no difference in DA distensibility or PWV, but slightly lower AA distensibility than in the patient group. With increasing age, there was a decrease in distensibility and an increase in PWV. After correcting for age, the AA maximum cross-sectional area was higher in bicuspid vs. tricuspid patients (12.97 [11.10, 15.59] vs. 10.06 [8.57, 12.04] cm2, p < 0.001), but there were no significant differences in AA distensibility (p = 0.099), DA distensibility (p = 0.498) or PWV (p = 0.235). Patients with BAV type-II valves demonstrated a significantly higher AA distensibility and lower PWV compared to type-I, despite a trend towards higher AA area. CONCLUSIONS: In patients with significant AS, BAV patients do not have increased aortic stiffness compared to those with TAV despite increased ascending aortic dimensions. Those with type-II BAV have less aortic stiffness despite greater dimensions. These results demonstrate a dissociation between aortic dilatation and stiffness and suggest that altered flow patterns may play a role. KEY POINTS: • Both cellular abnormalities secondary to genetic differences and abnormal flow patterns have been implicated in the pathophysiology of aortic dilatation and increased vascular complications associated with bicuspid aortic valves (BAV). • We demonstrate an increased ascending aortic size in patients with BAV and moderate to severe AS compared to TAV and controls, but no difference in aortic stiffness parameters, therefore suggesting a dissociation between dilatation and stiffness. • Sub-group analysis showed greater aortic size but lower stiffness parameters in those with BAV type-II AS compared to BAV type-I.


Subject(s)
Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/physiopathology , Aortic Valve/abnormalities , Heart Valve Diseases/diagnostic imaging , Magnetic Resonance Imaging , Tricuspid Valve/diagnostic imaging , Vascular Stiffness , Adult , Aged , Aorta/physiopathology , Aorta, Thoracic/diagnostic imaging , Aorta, Thoracic/pathology , Aorta, Thoracic/physiopathology , Aortic Valve/diagnostic imaging , Aortic Valve/pathology , Aortic Valve/physiopathology , Aortic Valve Stenosis/pathology , Bicuspid Aortic Valve Disease , Dilatation, Pathologic , Female , Heart Valve Diseases/pathology , Heart Valve Diseases/physiopathology , Humans , Male , Middle Aged , Pulse Wave Analysis , Tricuspid Valve/pathology , Tricuspid Valve/physiopathology
4.
Eur Heart J ; 38(16): 1222-1229, 2017 Apr 21.
Article in English | MEDLINE | ID: mdl-28204448

ABSTRACT

AIMS: To assess cardiovascular magnetic resonance (CMR) measured myocardial perfusion reserve (MPR) and exercise testing in asymptomatic patients with moderate-severe AS. METHODS AND RESULTS: Multi-centre, prospective, observational study, with blinded analysis of CMR data. Patients underwent adenosine stress CMR, symptom-limited exercise testing (ETT) and echocardiography and were followed up for 12-30 months. The primary outcome was a composite of: typical AS symptoms necessitating referral for AVR, cardiovascular death and major adverse cardiovascular events. 174 patients were recruited: mean age 66.2 ± 13.34 years, 76% male, peak velocity 3.86 ± 0.56 m/s and aortic valve area index 0.57 ± 0.14 cm2/m2. A primary outcome occurred in 47 (27%) patients over a median follow-up of 374 (IQR 351-498) days. The mean MPR in those with and without a primary outcome was 2.06 ± 0.65 and 2.34 ± 0.70 (P = 0.022), while the incidence of a symptom-limited ETT was 45.7% and 27.0% (P = 0.020), respectively. MPR showed moderate association with outcome area under curve (AUC) = 0.61 (0.52-0.71, P = 0.020), as did exercise testing (AUC = 0.59 (0.51-0.68, P = 0.027), with no significant difference between the two. CONCLUSIONS: MPR was associated with symptom-onset in initially asymptomatic patients with AS, but with moderate accuracy and was not superior to symptom-limited exercise testing. ClinicalTrials.gov (NCT01658345).


Subject(s)
Aortic Valve Stenosis/physiopathology , Coronary Circulation/physiology , Exercise Tolerance/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Area Under Curve , Exercise Test , Female , Humans , Magnetic Resonance Angiography , Male , Middle Aged , Prognosis , Prospective Studies , Young Adult
5.
Open Heart ; 10(2)2023 08.
Article in English | MEDLINE | ID: mdl-37586847

ABSTRACT

OBJECTIVE: To characterise cardiac remodelling, exercise capacity and fibroinflammatory biomarkers in patients with aortic stenosis (AS) with and without diabetes, and assess the impact of diabetes on outcomes. METHODS: Patients with moderate or severe AS with and without diabetes underwent echocardiography, stress cardiovascular magnetic resonance (CMR), cardiopulmonary exercise testing and plasma biomarker analysis. Primary endpoint for survival analysis was a composite of cardiovascular mortality, myocardial infarction, hospitalisation with heart failure, syncope or arrhythmia. Secondary endpoint was all-cause death. RESULTS: Diabetes (n=56) and non-diabetes groups (n=198) were well matched for age, sex, ethnicity, blood pressure and severity of AS. The diabetes group had higher body mass index, lower estimated glomerular filtration rate and higher rates of hypertension, hyperlipidaemia and symptoms of AS. Biventricular volumes and systolic function were similar, but the diabetes group had higher extracellular volume fraction (25.9%±3.1% vs 24.8%±2.4%, p=0.020), lower myocardial perfusion reserve (2.02±0.75 vs 2.34±0.68, p=0.046) and lower percentage predicted peak oxygen consumption (68%±21% vs 77%±17%, p=0.002) compared with the non-diabetes group. Higher levels of renin (log10renin: 3.27±0.59 vs 2.82±0.69 pg/mL, p<0.001) were found in diabetes. Multivariable Cox regression analysis showed diabetes was not associated with cardiovascular outcomes, but was independently associated with all-cause mortality (HR 2.04, 95% CI 1.05 to 4.00; p=0.037). CONCLUSIONS: In patients with moderate-to-severe AS, diabetes is associated with reduced exercise capacity, increased diffuse myocardial fibrosis and microvascular dysfunction, but not cardiovascular events despite a small increase in mortality.


Subject(s)
Aortic Valve Stenosis , Diabetes Mellitus , Humans , Exercise Tolerance , Renin , Aortic Valve Stenosis/diagnostic imaging , Heart
6.
JACC Cardiovasc Imaging ; 12(1): 96-105, 2019 01.
Article in English | MEDLINE | ID: mdl-29248646

ABSTRACT

OBJECTIVES: The aim of this study was to establish sex differences in remodeling and outcome in aortic stenosis (AS) and their associations with biomarkers of myocardial fibrosis. BACKGROUND: The remodeling response and timing of symptoms is highly variable in AS, and sex plays an important role. METHODS: A total of 174 patients (133 men, mean age 66.2 ± 13.3 years) with asymptomatic moderate to severe AS underwent comprehensive stress cardiac magnetic resonance imaging, transthoracic echocardiography, and biomarker analysis (matrix metalloproteinase [MMP]-2, -3, -7, -8, and -9; tissue inhibitor matrix metalloproteinases-1 and -4; syndecan-1 and -4; and N-terminal pro-B-type natriuretic peptide), and were followed up at 6-month intervals. A primary endpoint was a composite of typical AS symptoms necessitating referral for aortic valve replacement, cardiovascular death, or major adverse cardiovascular events. RESULTS: For a similar severity of AS, male patients demonstrated higher indexed left ventricular (LV) volumes and mass, more concentric remodeling (higher LV mass/volume), a trend to more late gadolinium enhancement (present in 51.1% men vs. 34.1% women; p = 0.057), and higher extracellular volume index than female patients (13.27 [interquartile range (IQR): 11.5 to 17.0] vs. 11.53 [IQR: 10.5 to 13.5] ml/m2, p = 0.017), with worse systolic and diastolic function and higher MMP-3 and syndecan-4 levels, whereas female patients had higher septal E/e'. Male sex was independently associated with indexed LV mass (ß = 13.32 [IQR: 9.59 to 17.05]; p < 0.001). During median follow-up of 374 (IQR: 351 to 498) days, a primary outcome, driven by spontaneous symptom onset, occurred in 21.8% of male and 43.9% of female patients (relative risk: 0.50 [95% confidence interval: 0.31 to 0.80]; p = 0.004). Measures of AS severity were associated with the primary outcome in both sexes, whereas N-terminal pro-B-type natriuretic peptide, MMP-3, and mass/volume were only associated in men. CONCLUSIONS: In AS, women tolerate pressure overload with less concentric remodeling and myocardial fibrosis but are more likely to develop symptoms. This may be related to higher wall stress and filling pressures in women.


Subject(s)
Aortic Valve Stenosis/complications , Health Status Disparities , Hypertrophy, Left Ventricular/etiology , Myocardium/pathology , Ventricular Dysfunction, Left/etiology , Ventricular Function, Left , Ventricular Remodeling , Adaptation, Physiological , Aged , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/pathology , Aortic Valve Stenosis/physiopathology , Biomarkers/blood , Disease Progression , Echocardiography , Female , Fibrosis , Humans , Hypertrophy, Left Ventricular/diagnostic imaging , Hypertrophy, Left Ventricular/pathology , Hypertrophy, Left Ventricular/physiopathology , Magnetic Resonance Imaging , Male , Middle Aged , Prognosis , Risk Assessment , Risk Factors , Severity of Illness Index , Sex Factors , Time Factors , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/pathology , Ventricular Dysfunction, Left/physiopathology
7.
BMJ Case Rep ; 11(1)2018 Nov 28.
Article in English | MEDLINE | ID: mdl-30567125

ABSTRACT

We describe the case of a 3-week postpartum 27-year-old woman who presented with chest pain to the emergency department shortly before developing cardiac arrest with refractory ventricular fibrillation. She was initially misdiagnosed and treated for presumed pulmonary embolism (PE) with thrombolysis. A total of 14 direct current cardioversion shocks were given and return of spontaneous circulation (ROSC) was achieved post thrombolysis. Subsequent CT pulmonary angiography excluded PE. A post-ROSC ECG demonstrated anterolateral ST elevation and she was transferred to the local cardiac unit for angiography. This revealed extensive dissection of the left anterior descending artery (LAD) with proximal occlusion. The diagnosis therefore was pregnancy-associated spontaneous artery dissection, a type of acute coronary syndrome. She received percutaneous intervention to her LAD with five drug-eluting stents. The patient survived and was discharged 5 days later. Her ventricular function is now grossly impaired, and had the correct diagnosis been arrived at sooner, this loss of function would have been less severe.


Subject(s)
Acute Coronary Syndrome/diagnosis , Chest Pain/diagnosis , Coronary Angiography/methods , Coronary Artery Disease/pathology , Heart Arrest/diagnosis , Pulmonary Embolism/therapy , Ventricular Fibrillation/diagnosis , Adult , Chest Pain/etiology , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/therapy , Diagnostic Errors , Drug-Eluting Stents/standards , Electric Countershock/methods , Electrocardiography/instrumentation , Female , Humans , Postpartum Period , Pregnancy , Pregnancy Complications , Pulmonary Embolism/diagnosis , Thrombolytic Therapy/methods , Treatment Outcome , Ventricular Fibrillation/complications , Ventricular Fibrillation/physiopathology
8.
BMJ Case Rep ; 20182018 Jun 06.
Article in English | MEDLINE | ID: mdl-29880624

ABSTRACT

A 41-year-old woman was visiting Oxford, where she had a sudden cardiac arrest. Cardiopulmonary resuscitation was started by a bystander until the paramedics arrived, who found her in ventricular fibrillation, and delivered three shocks. After 28 min she had return of spontaneous circulation. Emergency coronary angiography revealed normal coronary arteries. Echocardiography followed by a cardiac MRI showed non-dilated left ventricles with no evidence of late gadolinium enhancement. She had a single-chamber implantable-cardioverter defibrillator (ICD). A chest CT showed sternal fracture and subsegmental pulmonary embolism, for which she was anticoagulated and was discharged.Several days later, the patient presented to another hospital with atypical chest pain and dizziness. She had haemodynamic instability and echocardiography showed the ICD lead perforating through the right ventricle, with a large pericardial effusion and tamponade, for which pericardiocentesis was done. Afterwards, the patient had repositioning of the ICD lead safely.


Subject(s)
Cardiopulmonary Resuscitation/adverse effects , Defibrillators, Implantable/adverse effects , Heart Ventricles/injuries , Pericardial Effusion/diagnostic imaging , Pericardiocentesis , Ventricular Fibrillation/physiopathology , Adult , Cardiac Tamponade , Coronary Angiography , Death, Sudden, Cardiac , Female , Heart Ventricles/diagnostic imaging , Humans , Pericardial Effusion/etiology , Pericardial Effusion/therapy , Treatment Outcome , Ventricular Fibrillation/etiology , Ventricular Fibrillation/therapy
9.
Int J Cardiol ; 92(2-3): 247-51, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14659860

ABSTRACT

BACKGROUND: Vascular endothelial growth factor (VEGF) is a specific endothelial cell mitogen. It promotes re-endothelialisation of the damaged vessel surface seen after stenting. Stent thrombosis and in-stent restenosis are partly related to endothelial denudation caused by stent implantation. We propose using hydrocarbon polymer-coated stents immersed in VEGF to speed re-endothelialisation and reduce the risk of stent thrombosis and restenosis. METHODS: Stents (3 x 20 mm) were immersed in VEGF solutions and maximal VEGF absorption calculated. VEGF release from these stents was measured in a perfusion circuit. Delivery of VEGF to arterial wall was measured. Sterile VEGF-loaded stents were cultured with human umbilical vein endothelial cells. RESULTS: 18.5 +/- 4.1 microg VEGF was absorbed, 80% of which was released over 9 days; 11 +/- 6.8% of the initial VEGF loaded was delivered to the vessel wall. Cells exposed to VEGF-eluting stents showed an 11% increase in growth relative to controls. CONCLUSION: VEGF may be a candidate for stent-based delivery and may increase the rate of endothelialisation in vivo.


Subject(s)
Stents , Vascular Endothelial Growth Factor A/administration & dosage , Cells, Cultured , Coronary Stenosis , Endothelium, Vascular/growth & development , Equipment Design , Humans , In Vitro Techniques , Vascular Endothelial Growth Factor A/pharmacology
10.
J Invasive Cardiol ; 15(12): 688-92, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14660819

ABSTRACT

Local drug delivery by stent can reduce in-stent restenosis. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen. After stenting, the arterial wall is almost denuded of endothelium. This loss of endothelium contributes to the smooth muscle cell (SMC) proliferation seen in restenosis, since the endothelium actively inhibits SMC hyperplasia. Over time, the endothelium recovers and SMC hyperplasia is arrested. The capacity of VEGF-coated stents to accelerate re-endothelialization, and to therefore reduce restenosis and thrombosis, was tested in this study. Radiolabeled VEGF was absorbed onto stents and released over nine days in an in vitro perfusion circuit. VEGF-coated stents were deployed in arterial segments to study local tissue release. A New Zealand White rabbit iliac artery model for stent implantation was used. Re-endothelialization and thrombosis were assessed after seven days. Further animals were examined 28 days post-procedure for in-stent restenosis. Stented vessels were resin-embedded, sectioned and stained. Intimal thickening was calculated using computerized morphometry. In vitro, the stents released 80% of the initial load over nine days. At seven days, thrombus was significantly reduced (12.5 mg for controls versus 0 mg for VEGF; p = 0.014). No beneficial effect was seen on endothelialization, nor on intimal hyperplasia. Neointimal area was 2.2 0.9 mm2 for controls versus 2.4 1.8 mm2 for VEGF (p = 0.8). These VEGF-eluting stents do not accelerate re-endothelialization or inhibit restenosis. Stent thrombosis appears to be reduced, which may make these stents less thrombogenic and be valuable in higher-risk cases.


Subject(s)
Coated Materials, Biocompatible/therapeutic use , Stents , Vascular Endothelial Growth Factor A/therapeutic use , Animals , Blood Vessel Prosthesis Implantation , Endothelium, Vascular/pathology , Endothelium, Vascular/surgery , Graft Occlusion, Vascular/etiology , Graft Occlusion, Vascular/mortality , Hyperplasia/mortality , Hyperplasia/therapy , Male , Rabbits , Thrombosis/mortality , Thrombosis/therapy , Time Factors , Treatment Outcome , Tunica Intima/pathology , Tunica Intima/surgery
11.
J Invasive Cardiol ; 18(9): 417-22, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16954580

ABSTRACT

OBJECTIVE: Stent thrombosis and in-stent restenosis remain problematic despite drug-eluting stents (DES), especially in diabetic patients and in those with small-vessel disease. Eptifibatide inhibits the platelet glycoprotein IIb/IIIa and smooth muscle cell (SMC) avb3 receptor, thus potentially influencing both thrombosis and proliferation. The aim of the present studies was to examine the absorption and elution characteristics of eptifibatide on polymer-coated stents and investigated their effect on SMC proliferation, platelet deposition and platelet aggregation in vitro. METHODS AND RESULTS: Polymer-mixed eptifibatide and H3-labeled eptifibatide were loaded onto bare metal stents. A maximum of 111 mcg of eptifibatide was loaded onto 3.0 x 18 mm stents. Drug elution characteristics were tested in a PBS perfusion circuit. Elution profile consisted of an early rapid phase (24% +/- 0.03 loss over 1 hour) followed by a sustained release with 44% +/- 2.30 still present on the stent after 30 days. Eluted eptifibatide significantly inhibited adenosine diphosphate (ADP)-induced platelet aggregation by 95% +/- 0.70 (p < 0.01). Efficacy of stents eluting eptifibatide for antiplatelet effect was determined by measuring deposition of 111indium-labeled platelets on stents. Platelet deposition was significantly reduced by 48% +/- 6 in comparison to controls (p = 0.0065). Finally, drug-loaded stents were placed in SMC culture and showed a distinct zone of cell growth inhibition within 1 mm2 (88 +/- 22 vs. 208 +/- 23 SMCs in control), and within 2 mm2 of stent (131 +/- 32 vs. 191 +/- 23 SMCs in control) (both p < 0.01). CONCLUSIONS: Eptifibatide can be successfully loaded onto stents. It elutes in a predictable manner, significantly inhibiting platelet deposition, aggregation and SMC proliferation in vitro. These studies pave the way to developing stent-based delivery of a potent antiplatelet agent, which additionally may inhibit SMC activity.


Subject(s)
Cell Proliferation/drug effects , Coronary Thrombosis/prevention & control , Peptides/pharmacokinetics , Platelet Aggregation Inhibitors/pharmacokinetics , Stents , Angioplasty, Balloon, Coronary/instrumentation , Angioplasty, Balloon, Coronary/methods , Cells, Cultured , Coated Materials, Biocompatible , Coronary Restenosis/prevention & control , Coronary Restenosis/therapy , Coronary Thrombosis/therapy , Drug Delivery Systems , Eptifibatide , Humans , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Peptides/administration & dosage , Peptides/pharmacology , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/pharmacology , Polymers , Thrombolytic Therapy/methods
12.
Clin Sci (Lond) ; 103(4): 347-53, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12241533

ABSTRACT

Local drug delivery by coronary stents is of current research interest. Organ culture of human vascular tissue is a model of intimal hyperplasia. We report an ex vivo organ culture model of stented vessels. This allows stent-artery interactions to be studied in living tissue. The recognized anti-restenosis agent paclitaxel was chosen to test the organ culture model. Mammary artery specimens were cultured 'closed' (i.e. without opening them flat) for 72 h. Phosphocholine-coated stents, half of them loaded with the anti-restenosis drug paclitaxel, were implanted. The absorption and elution characteristics of paclitaxel were established. Artery tissue remained viable at 72 h when cultured closed, despite stent implantation. Specimens developed smooth muscle cell proliferation. The stents absorbed up to 127+/-29 microg of paclitaxel, with a biphasic elution curve. A mean of 13% of the absorbed paclitaxel remained after a 24 h perfusion. In mammary artery, these paclitaxel stents reduced or abolished smooth muscle cell proliferation compared with controls. This model allows the effects of stenting on human arterial tissue to be studied for at least 72 h, long enough to demonstrate effects on smooth muscle cell proliferation. Phosphocholine-coated stents absorb adequate doses of paclitaxel, which is eluted gradually, inhibiting muscle cell proliferation. Such an organ culture model of stented mammary artery will provide useful data in addition to that from animal or cell culture models of drug-eluting stents.


Subject(s)
Coronary Artery Disease/pathology , Models, Cardiovascular , Muscle, Smooth, Vascular/metabolism , Paclitaxel/pharmacokinetics , Stents , Cell Division/drug effects , Coated Materials, Biocompatible , Drug Delivery Systems , Graft Occlusion, Vascular/prevention & control , Humans , Mammary Arteries/metabolism , Muscle, Smooth, Vascular/cytology , Organ Culture Techniques/methods , Phosphorylcholine , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL